Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
Syndecan-1 (SDC1, CD138) is a key cell surface adhesion molecule essential for maintaining cell morphology and interaction with the surrounding microenvironment. Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion and angiogenesis, and is asso...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Impact Journals LLC
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745686/ |
| id |
pubmed-4745686 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-47456862016-02-23 Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine Akl, Mohamed R. Nagpal, Poonam Ayoub, Nehad M. Prabhu, Sathyen A. Gliksman, Matthew Tai, Betty Hatipoglu, Ahmet Goy, Andre Suh, K. Stephen Review Syndecan-1 (SDC1, CD138) is a key cell surface adhesion molecule essential for maintaining cell morphology and interaction with the surrounding microenvironment. Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion and angiogenesis, and is associated with relapse through chemoresistance. SDC1 expression level is also associated with responses to chemotherapy and with prognosis in multiple solid and hematological cancers, including multiple myeloma and Hodgkin lymphoma. At the tissue level, the expression levels of SDC1 and the released extracellular domain of SDC1 correlate with tumor malignancy, phenotype, and metastatic potential for both solid and hematological tumors in a tissue-specific manner. The SDC1 expression profile varies among cancer types, but the differential expression signatures between normal and cancer cells in epithelial and stromal compartments are directly associated with aggressiveness of tumors and patient's clinical outcome and survival. Therefore, relevant biomarkers of SDC signaling may be useful for selecting patients that would most likely respond to a particular therapy at the time of diagnosis or perhaps for predicting relapse. In addition, the reciprocal expression signature of SDC between tumor epithelial and stromal compartments may have synergistic value for patient selection and the prediction of clinical outcome. Impact Journals LLC 2015-07-22 /pmc/articles/PMC4745686/ /pubmed/26293675 Text en Copyright: © 2015 Akl et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Akl, Mohamed R. Nagpal, Poonam Ayoub, Nehad M. Prabhu, Sathyen A. Gliksman, Matthew Tai, Betty Hatipoglu, Ahmet Goy, Andre Suh, K. Stephen |
| spellingShingle |
Akl, Mohamed R. Nagpal, Poonam Ayoub, Nehad M. Prabhu, Sathyen A. Gliksman, Matthew Tai, Betty Hatipoglu, Ahmet Goy, Andre Suh, K. Stephen Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| author_facet |
Akl, Mohamed R. Nagpal, Poonam Ayoub, Nehad M. Prabhu, Sathyen A. Gliksman, Matthew Tai, Betty Hatipoglu, Ahmet Goy, Andre Suh, K. Stephen |
| author_sort |
Akl, Mohamed R. |
| title |
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| title_short |
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| title_full |
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| title_fullStr |
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| title_full_unstemmed |
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| title_sort |
molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine |
| description |
Syndecan-1 (SDC1, CD138) is a key cell surface adhesion molecule essential for maintaining cell morphology and interaction with the surrounding microenvironment. Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion and angiogenesis, and is associated with relapse through chemoresistance. SDC1 expression level is also associated with responses to chemotherapy and with prognosis in multiple solid and hematological cancers, including multiple myeloma and Hodgkin lymphoma. At the tissue level, the expression levels of SDC1 and the released extracellular domain of SDC1 correlate with tumor malignancy, phenotype, and metastatic potential for both solid and hematological tumors in a tissue-specific manner. The SDC1 expression profile varies among cancer types, but the differential expression signatures between normal and cancer cells in epithelial and stromal compartments are directly associated with aggressiveness of tumors and patient's clinical outcome and survival. Therefore, relevant biomarkers of SDC signaling may be useful for selecting patients that would most likely respond to a particular therapy at the time of diagnosis or perhaps for predicting relapse. In addition, the reciprocal expression signature of SDC between tumor epithelial and stromal compartments may have synergistic value for patient selection and the prediction of clinical outcome. |
| publisher |
Impact Journals LLC |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745686/ |
| _version_ |
1613535512007540736 |